Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Change in central macular thickness (CMT ) in microns
研究概览
简要总结
describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR
详细描述
Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021
After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.
Investigators collected and recorded the following data:
- Age
- Gender
- Systemic hypertension (present or not)
- Smoking (Yes / No)
- Best corrected visual acuity (BCVA) (baseline, final)
- Central macular thickness (CMT) (baseline, final)
- Serous detachment Height (SDH) (baseline, final)
- Duration of Follow-up ( in months)
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 16 Years 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac.
排除标准
- •• CSCR treated by other modalities
- •CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac
结局指标
主要结局
Change in central macular thickness (CMT ) in microns
时间窗: (baseline, 6 months)
reduction in CMT after therapy
Change in serous detachment height (SDH) in microns
时间窗: (baseline, 6 months)
reduction in SDH after therapy
次要结局
- Duration of Follow-up ( in months)((baseline, 6 months))
- Change in BCVA((baseline, 6 months))
- Complications (Eplerenone, Aflibercept, and nepafenac)((baseline, 6 months))
研究者
Wael Ahmed Ewais
Associate professor of ophthalmology
Dar El Oyoun Hospital